Navigation Links
Presentation at the 14th International Conference on Prenatal Diagnosis and Therapy Highlights Biocept's I.D.Rh(D) Prenatal Diagnostic
Date:6/3/2008

SAN DIEGO, June 3 /PRNewswire/ -- A presentation at the 14th International Conference on Prenatal Diagnosis and Therapy (ISPD) in Vancouver, BC, will highlight Biocept's I.D.Rh(D) Prenatal Diagnostic. I.D.Rh(D) is the first in a series of noninvasive prenatal diagnostic tests that can be performed with a simple maternal blood sample.

The I.D.Rh(D) test diagnoses the Rh(D) status of a fetus in an Rh(D) negative pregnancy, and can be performed as early as ten weeks of gestation. The test isolates fetal DNA circulating in the mother's whole blood, using Biocept's proprietary I.D.(TM) (Isolating Fetal DNA) platform technology (U.S. patents pending). The fetal DNA is analyzed in Biocept's CLIA-accredited clinical laboratory to determine Rh(D) genotype. Similar noninvasive tests have been available routinely in some countries outside the US.

The presentation, to be given by Andrew Brooks, Ph.D., University of Medicine and Dentistry of New Jersey, concludes that isolation of fetal DNA from maternal whole blood for quantitative real-time PCR and Rh(D) genotyping is suitable for routine testing. Testing of multiple markers and controls, which I.D.Rh(D) offers, allows for a high degree of accuracy.

"We are very pleased to see our excellent clinical results validated in an independently reviewed scientific forum such as ISPD," said Gordon F. Janko, president and CEO of Biocept. "The I.D.Rh(D) test, which is now being used commercially, is an important step forward in noninvasive prenatal testing, and provides a higher level of personalized medicine for patients. It is the first of several noninvasive prenatal diagnostics developed in Biocept's laboratories, based on our novel and proprietary technology."

I.D.Rh(D) is the only fetal Rh(D) diagnostic that identifies fetal DNA in maternal blood in all cases in which a diagnosis can be delivered-whether the fetus is male or female, Rh(D) negative or positive.

Until now, the only tests available to definitively diagnose fetal Rh(D) genotype required invasive procedures such as amniocentesis or chorionic villus sampling (CVS), which carry their own risks to the fetus. For this reason, physicians have routinely administered anti-D immune globulin injections, a human blood product, to all Rh(D) negative women at 28-29 weeks of gestation.

About Biocept

Biocept, an emerging biotechnology leader, engineers novel solutions that provide the foundation for a new class of diagnostic assays. Biocept is based in San Diego, California, a major center for academic and industrial life sciences research. Founded in 1997, the company is privately held and draws on a scientific team rich in experience in life science. Its CLIA-accredited clinical laboratory is accredited by the College of American Pathologists and holds licenses in California and other states as required.


'/>"/>
SOURCE Biocept
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
2. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
3. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
4. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
5. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
6. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
7. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
8. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
9. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
10. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
11. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO Thad ... Officer Forum on March 23-24 in San Diego. The event is a gathering ... industries. , Benchworks Vice President Christian Meyer will also participate in the forum. ...
(Date:3/22/2017)... , ... March 21, 2017 , ... The Conference Forum ... (CMO Summit) to be held on May 10-11, 2017, at the Colonnade Hotel in ... specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical ...
(Date:3/22/2017)... ... March 21, 2017 , ... Functional near-infrared spectroscopy (fNIRS), an optical ... as a way to track the brain’s response to acute pain in adults and ... pressor test ,” published today in the journal Neurophotonics , by SPIE, ...
(Date:3/22/2017)... ... March 22, 2017 , ... March 22, 2017...Council for Agricultural Science and Technology, ... that utilizes technological innovation in smart, sustainable ways. Humans depend on plants for food, ... and environmental stability. This paper is the first in a series that connects science ...
Breaking Biology Technology:
(Date:3/6/2017)... Calif. , March 6, 2017 ... and sales technology, today announced Predictive Sales Coach ... for infusing actionable sales intelligence into Salesforce. This ... automatically enable their sales organizations with deep knowledge ... that allow for intelligent engagement. Predictive Sales Coach ...
(Date:3/1/2017)...  Aware, Inc. (NASDAQ: AWRE), a leading supplier of ... Moberg has resigned, effective March 3, 2017, as ... and Treasurer of Aware citing a desire to retire.  ... of the Board of Directors of Aware. ... and co-President, General Counsel has been named Chief Executive ...
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
Breaking Biology News(10 mins):